Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2016

01-04-2016 | Erratum

Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases

Authors: Siqing Fu, Kirk S. Culotta, Gerald S. Falchook, David S. Hong, Alan L. Myers, Yan-Ping Zhang, Aung Naing, Filip Janku, Ming-Mo Hou, Razelle Kurzrock

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2016

Login to get access

Excerpt

In the original article, corresponding author’s given name and family name are flipped. It should be “Siqing Fu” rather than “Fu Siqing”. …
Metadata
Title
Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases
Authors
Siqing Fu
Kirk S. Culotta
Gerald S. Falchook
David S. Hong
Alan L. Myers
Yan-Ping Zhang
Aung Naing
Filip Janku
Ming-Mo Hou
Razelle Kurzrock
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3002-1

Other articles of this Issue 4/2016

Cancer Chemotherapy and Pharmacology 4/2016 Go to the issue

Original Article

Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients

Original Article

Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity

Review Article

Unique features of trabectedin mechanism of action

Original Article

Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial)

Original Article

Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients

Short Communication

Oxytocin as a protective agent in cisplatin-induced ototoxicity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits